Lexaria Bioscience logo
Lexaria Bioscience
LEXX | NASDAQ
Chart Builder DCF Calculator
$4.41
-$0.03 (-0.68%)
At close: Nov 16, 2026, 4:00 PM ET
$4.11
-$0.30 (-6.80%)
After-hours: Nov 16, 2026, 4:23 PM ET

Lexaria Bioscience Company Profile

Company profile explained

Company Profile

Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.

Key Executives

Name Position
Richard C. Christopher Chief Executive Officer & Director
Michael Shankman Chief Financial Officer
C. Michael Gibson Chief Medical Advisor & Member of Scientific Advisory Board
John Docherty Chairman of the Scientific Advisory Board, Chief Scientific Officer, President & Director
Kristin Hamilton Director of Operations
Vanessa Carle Head of Legal

Latest SEC Filings

Date Type Title
Oct 13, 2026 EFFECT Filing
Oct 13, 2026 424B3 Filing
Oct 02, 2026 S-3 Filing
Sep 21, 2026 D Filing
Sep 09, 2026 8-K Current Report
Sep 01, 2026 8-K Current Report
Aug 17, 2026 8-K Current Report
Aug 10, 2026 8-K Current Report
Jul 30, 2026 8-K Current Report
Jul 13, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Lexaria Bioscience
Lexaria Bioscience logo
Country Canada
IPO Date Jan 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Richard C. Christopher

Contact Details

100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada

Stock Details

Ticker Symbol LEXX
Exchange NASDAQ
Fiscal Year September - August
Reporting Currency USD
CIK Code 0001348362
CUSIP Number 52886N604
ISIN Number US52886N6040
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.